Paul Wibbels, MD
Internal Medicine · Hastings, NENPI 1336142900
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 591 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,821 and has fallen 80.3% since, to $358 in 2025. Among internal medicine clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 591 payments — averaging $15.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$1K
- Novo Nordisk$984
- Lilly USA, LLC$928
- Pfizer$661
- Amgen$591
- plus $4K from 31 others
What the payments were for
- Food & beverage$9,085100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $1,285 |
| AbbVie(2 entities) | 69 | $1,055 |
| Novo Nordisk | 70 | $984 |
| Lilly USA, LLC | 64 | $928 |
| Pfizer | 84 | $661 |
| Amgen | 47 | $591 |
| Boehringer Ingelheim | 50 | $564 |
| Aimmune Therapeutics, Inc. | 4 | $353 |
| Johnson & Johnson | 15 | $313 |
| GSK | 33 | $301 |
| Sanofi-aventis U.S. LLC | 21 | $287 |
| Novartis | 20 | $284 |
| Exact Sciences | 20 | $263 |
| Astellas Pharma US Inc | 13 | $232 |
| Bayer | 13 | $187 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $177 |
| Mylan Specialty L.p. | 6 | $87 |
| Merck | 6 | $85 |
| Xeris Pharmaceuticals, Inc. | 4 | $59 |
| Dexcom, Inc. | 4 | $59 |
| Grifols USA, LLC | 3 | $48 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Nestle Healthcare Nutrition Inc. | 2 | $28 |
| Genentech USA, Inc. | 2 | $27 |
| Neurocrine Biosciences, Inc. | 2 | $26 |
| Biogen | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Baxter Healthcare | 1 | $13 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,085 in reported general payments places this provider in the 95th percentile of 570 internal medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 280 | $230,719 |
| OzempicSemaglutide | 149 | $150,833 |
| Tresiba Flextouch U-200Insulin Degludec | 53 | $112,353 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $45,401 |
| Tresiba Flextouch U-100Insulin Degludec | 45 | $45,273 |
| MounjaroTirzepatide | 33 | $45,104 |
| XareltoRivaroxaban | 43 | $38,884 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $37,376 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $35,194 |
| RybelsusSemaglutide | 23 | $32,319 |
| Repatha SureclickEvolocumab | 51 | $31,362 |
| FarxigaDapagliflozin Propanediol | 34 | $27,296 |
| JanuviaSitagliptin Phosphate | 44 | $27,248 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 32 | $27,183 |
| JardianceEmpagliflozin | 29 | $23,891 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $661 | $230,719280 claims |
| Novo NordiskOzempic, Rybelsus | $984 | $183,151172 claims |
| Lilly USA, LLCMounjaro, Trulicity | $928 | $55,80745 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $301 | $43,84459 claims |
| Johnson & JohnsonXarelto | $313 | $38,88443 claims |
| AstraZenecaFarxiga, Nexium, Symbicort | $1,285 | $38,77661 claims |
| MerckJanuvia | $85 | $27,24844 claims |
| Boehringer IngelheimJardiance | $564 | $23,89129 claims |
| Astellas Pharma US IncMyrbetriq | $232 | $23,67438 claims |
| AbbVieLinzess | $1,055 | $17,85218 claims |
| NovartisEntresto | $284 | $14,78522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 570 internal medicine providers in Nebraska.
Other internal medicine in Hastings
- Justin WenburgHastings$10K
- Douglas HentzenHastings$9K
- Matthew StrittHastings$6K
- Michelle SeizysHastings$5K
- Richard FrenchHastings$4K
- Brian BoerOmaha$142K
- Sherri ThomasLincoln$136K
- Adam BurdorfOmaha$29K
- David SharpOmaha$26K
- David ShinOmaha$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.